Plus Therapeutics/$PSTV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Plus Therapeutics
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Ticker
$PSTV
Sector
Primary listing
Employees
28
Headquarters
Website
PSTV Metrics
BasicAdvanced
$33M
-
-$7.25
1.02
-
Price and volume
Market cap
$33M
Beta
1.02
52-week high
$5.35
52-week low
$2.90
Financial strength
Current ratio
1.232
Quick ratio
0.726
Long term debt to equity
0.375
Total debt to equity
20.546
Interest coverage (TTM)
-27.92%
Profitability
EBITDA (TTM)
-14.853
Gross margin (TTM)
-60.73%
Net profit margin (TTM)
-429.43%
Operating margin (TTM)
-293.46%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-83.29%
Return on equity (TTM)
903.94%
Valuation
Price to revenue (TTM)
2.866
Price to book
6.66
Price to tangible book (TTM)
8.09
Price to free cash flow (TTM)
-0.717
Free cash flow yield (TTM)
-139.52%
Free cash flow per share (TTM)
-6.697
Growth
Revenue change (TTM)
-10.49%
Earnings per share change (TTM)
-87.61%
3-year revenue growth (CAGR)
185.50%
10-year revenue growth (CAGR)
-7.73%
3-year earnings per share growth (CAGR)
-70.75%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Plus Therapeutics stock?
Plus Therapeutics (PSTV) has a market cap of $33M as of April 12, 2026.
What is the P/E ratio for Plus Therapeutics stock?
The price to earnings (P/E) ratio for Plus Therapeutics (PSTV) stock is 0 as of April 12, 2026.
Does Plus Therapeutics stock pay dividends?
No, Plus Therapeutics (PSTV) stock does not pay dividends to its shareholders as of April 12, 2026.
When is the next Plus Therapeutics dividend payment date?
Plus Therapeutics (PSTV) stock does not pay dividends to its shareholders.
What is the beta indicator for Plus Therapeutics?
Plus Therapeutics (PSTV) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.